期刊文献+

改良休克指数与妊娠期高血压病患者产后出血相关性研究

Study of relationship between MSI and postpartum hemorrhage in patients with HDP
下载PDF
导出
摘要 目的探讨改良休克指数(MSI)在妊娠期高血压患者产后出血的相关性及应用.方法根据妊娠期高血压患者是否发生产后出血进行分组比较,使用诊断时MSI对产后出血进行预测,以ROC曲线验证预测模型区分度.结果1381例中共64例患者出现产后出血.两组患者年龄、临床诊断、疾病严重程度、分娩孕周、BMI及产次的差异均无统计学意义(P>0.05).并发症及合并症,产后出血组仅中央性前置胎盘发生率高于无产后出血组(P<0.05).产后出血组MSI高于无产后出血组(0.91±0.12vs.0.87±0.13,P=0.006),校正混杂因素后MSI是产后出血独立危险因素.3个预测模型ROC曲线下面积分别为0.744、0.758及0.772.结论诊断妊娠期高血压病时的MSI对于患者产后出血具有预警作用. Objective To explore the correlation and application of MSI in postpartum hemorrhage with HDP.Methods According to the occurrence of postpartum hemorrhage in GHD.the postpartum hemorrhage was predicted by MSI.and the model differentiation was verified by ROC curve.Results A total of 64 patients had postpartum hemorrhage.There was no statistical difference in age.disease severity,gestational age.BMI and parity between the two groups.Only the incidence of central placenta previa in the postpartum hemorrhage group was higher than that in the control group(P<0.05).The MSI in the postpartum hemorrhage group was higher.It was suggested that MSI was an independent risk factor for postpartum hemorrhage.The AUC of the three prediction models were 0.744.0.758 and 0.772 respectively.Conclusion MSI in the diagnosis of HDP has an early warning effect on postpartum hemorrhage.
作者 陈丽春 谢培坤 余倩 张华乐 CHEN Lichun;XIE Peikun;YU Qian;ZHANG Huale(Fujian Maternity and Child Health Hospital,Fuzhou,Fujian 350001,China)
出处 《福建医药杂志》 CAS 2022年第1期8-11,共4页 Fujian Medical Journal
基金 福建医科大学大学生创新创业训练计划项目(L21068) 福建省妇幼保健院科研基金计划项目(妇幼YCXM19-35) 福建省卫生健康科研人才培养项目青年科研课题(2019-2-10)。
关键词 妊娠期高血压疾病 产后出血 改良休克指数 HDP postpartum hemorrhage MSI
  • 相关文献

参考文献3

二级参考文献47

  • 1American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy.Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy [J]. Obstet Gynecol, 2013, 122(5):1122-1131.
  • 2Magee LA, Pels A, Helewa M, et al.Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary[J]. J Obstet Gynaecol Can, 2014, 36(5):416-441.
  • 3Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance[J]. BMJ, 2010, 341 :c2207.
  • 4Lowe SA, Bowyer L, Lust K, et al. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014[J]. Aust N Z J Obstet Gynaecol, 2015, 55(1):11-16.
  • 5Campos-Outcah D Sr. US Preventive Services Task Force: the gold standard of evidence-based prevention[J]. J Fam Pract, 2005, 54(6):517-519.
  • 6Magee LA, Hdewa M, Momquin JM, et al. Diagnosis, evaluation,and management of the hypertensive disorders of pregnancy[J]. J Obstet Gynaeeol Can, 2008, 30 (Suppl): S1-48.
  • 7Cote AM, Brown MA, Laln E, et al. Diagnostic accuracy of urinary spot protein: creatiniue ratio for proteinuria in hypertensive pregnant women: systematic review[J]. BMJ, 2008, 336(7651): 1003-1006.
  • 8Churchill D, Beevers GD, Meher S, et al, Diuretics for preventing pre-eclampsia[J]. Cochrane Database Syst Rev, 2007, 24 (1):CD004451.
  • 9McCoy S, Baldwin K. Pharmacotherapeutie options for the treatment of preeelampsia[J]. Am J Health Syst Pharm, 2009, 66(4):337-344.
  • 10Duley L, Gfilmezoglu AM, Chou D. Magnesium sulphate versus lytic cocktail for eclampsia[J]. Cochrane Database Syst Rev, 2010, 8(9):CD002960.

共引文献1270

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部